PST13-RK

General Information


DRACP ID  DRACP00200

Peptide Name   PST13-RK

Sequence  KKKFPWWWPFKKK

Sequence Length  13

UniProt ID  Not available

PubChem CID  Not available

Origin  Derivative of tritrpticin

Type  Native peptide

Classification

  

Active ACP



Activity Information


Cell Line Disease Cancer Classified Activity Assay Testing Time Literature
A549 Lung adenocarcinoma Carcinoma IC50=90 µg/ml MTT assay Not available 1
MDA-MB-361 Breast adenocarcinoma Carcinoma IC50=80 µg/ml MTT assay Not available 1

Hemolytic Activity  Not available

Normal (non-cancerous) Cytotoxicity  NIH-3T3 (mouse): IC50=83 µg/ml

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Anticancer; Antimicrobial



Structure Information


PDB ID  Not available

Predicted Structure  DRACP00200

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Free

C-terminal Modification  Amidation

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C97H136N22O14

Absent amino acids  ACDEGHILMNQRSTVY

Common amino acids  K

Mass  204849

Pl  11.5

Basic residues  6

Acidic residues  0

Hydrophobic residues  5

Net charge  6

Boman Index  -2035

Hydrophobicity  -182.31

Aliphatic Index  0

Half Life 
  Mammalian: 1.3 hour
  Yeast: 3 min
  E.coli: 2 min

Extinction Coefficient cystines  16500

Absorbance 280nm  1375

Polar residues  0

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 18815734

Title  Effect of dimerization of a beta-turn antimicrobial peptide, PST13-RK, on antimicrobial activity and mammalian cell toxicity

Doi 10.1007/s10529-008-9848-5

Year  2009

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DRACP is developed by Dr.Zheng's team.